Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 886 Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The pattern and risk factors of recurrence of proximal gastric cancer after curative resection

  2013cited by this paper
• Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

  2013cited by this paper
• Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

  2013cited by this paper
• S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis.

  2012cited by this paper
• Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.

  2012cited by this paper
• Significance of palliative gastrectomy for late‐stage gastric cancer patients

  2012cited by this paper
• Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.

  2012cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

  2012cited by this paper
• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  2012cited by this paper
• Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

  2011cited by this paper
• Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.

  2011cited by this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial

  2011cited by this paper
• Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer

  2011cited by this paper
• Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy

  2010cited by this paper
• Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

  2010cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2010cited by this paper
• An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.

  2010cited by this paper
• Gastric Cancer: Epidemiology and Risk Factors

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center

  2010cited by this paper
• Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer

  2010influential reference
• Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy

  2010cited by this paper
• Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

  2010cited by this paper
• Predictive Factors Improving Survival After Gastrectomy in Gastric Cancer Patients with Peritoneal Carcinomatosis

  2010cited by this paper
• Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

  2010cited by this paper
• Evaluation of the Cost-Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Peritonectomy) at the St George Hospital Peritoneal Surface Malignancy Program

  2010influential reference
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

  2010cited by this paper
• Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and Korea

  2009cited by this paper
• Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

  2009cited by this paper
• Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil

  2009cited by this paper
• Signet Ring Cell Histology is an Independent Predictor of Poor Prognosis in Gastric Adenocarcinoma Regardless of Tumoral Clinical Presentation

  2009cited by this paper
• Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery

  2009cited by this paper
• The fluorometric microculture cytotoxicity assay

  2008cited by this paper
• Locoregional treatment of peritoneal carcinomatosis from gastric cancer

  2008cited by this paper
• 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

  2008cited by this paper
• Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center

  2008cited by this paper
• Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer.

  2008cited by this paper
• Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

  2008cited by this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.

  2008cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008cited by this paper
• Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

  2008cited by this paper
• Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

  2008cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2008cited by this paper
• Comparison of Two Kinds of Intraperitoneal Chemotherapy Following Complete Cytoreductive Surgery of Colorectal Peritoneal Carcinomatosis

  2007cited by this paper
• Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis

  2007cited by this paper
• Advanced Gastric Carcinoma with Signet Ring Cell Histology

  2007cited by this paper
• Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy

  2007cited by this paper
• Multivariate prognostic study on large gastric cancer

  2007cited by this paper
• Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

  2006cited by this paper
• Trends in the measurement of health utilities in published cost-utility analyses.

  2006cited by this paper
• Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field

  2006cited by this paper
• Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question

  2006cited by this paper
• The general rules for the gastric cancer study in surgery and pathology

  2006cited by this paper
• Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

  2006cited by this paper
• Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion

  2005cited by this paper
• Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

  2005cited by this paper
• Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion

  2005cited by this paper
• [Cost of an intraperitoneal chemohyperthermia (IPCH) related to cytoreductive surgery].

  2005influential reference
• Strategies for the Prevention and Treatment of Peritoneal Carcinomatosis from Gastrointestinal Cancer

  2005cited by this paper
• The history of gastric cancer: legends and chronicles

  2005cited by this paper
• Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

  2004cited by this paper
• Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.

  2004cited by this paper
• Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

  2004cited by this paper
• Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.

  2004cited by this paper
• Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

  2004cited by this paper
• Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.

  2004influential reference
• Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer

  2004cited by this paper
• Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.

  2003cited by this paper
• Carrier solutions for intraperitoneal chemotherapy.

  2003cited by this paper
• Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma.

  2003cited by this paper
• The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study

  2003cited by this paper
• Incidence and Factors Associated with Recurrence Patterns after Intended Curative Surgery for Gastric Cancer

  2003cited by this paper
• Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

  2003cited by this paper
• Gastric cancer: epidemiology, pathology and treatment.

  2003cited by this paper
• Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions

  2003cited by this paper
• Increased in vitro cellular drug resistance is related to poor outcome in high‐risk childhood acute lymphoblastic leukaemia

  2003cited by this paper
• Value of palliative resection in gastric cancer

  2002cited by this paper
• Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.

  2002cited by this paper
• Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro

  2002cited by this paper
• Human Pharmacokinetic Study of Heated Intraperitoneal Oxaliplatin in Increasingly Hypotonic Solutions after Complete Resection of Peritoneal Carcinomatosis

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Chemotherapy in gastric cancer: a review and updated meta-analysis.

  2002cited by this paper
• Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer

  2002cited by this paper
• Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy

  2001cited by this paper
• Prognostic Value of Carcinoembryonic Antigen, CA 19-9 and CA 72-4 in Gastric Carcinoma

  2001cited by this paper
• Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial

  2001cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  2001cited by this paper
• Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

  2001cited by this paper
• Tumor load and surgical palliation in gastric cancer.

  2001cited by this paper
• Peritoneal carcinomatosis from non‐gynecologic malignancies

  2000cited by this paper
• Prognostic Significance of CEA, CA 19-9 and CA 72-4 Preoperative Serum Levels in Gastric Carcinoma

  1999cited by this paper
• Management of peritoneal-surface malignancy: the surgeon’s role

  1999cited by this paper
• Administration in a Hypotonic Solution Is Preferable to Dose Escalation in Intraperitoneal Cisplatin Chemotherapy for Peritoneal Carcinomatosis in Rats

  1999cited by this paper
• Status of clinical hyperthermia.

  1999cited by this paper
• Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.

  1999cited by this paper
• Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy

  1999cited by this paper
• Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.

  1998cited by this paper
• Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

  1997cited by this paper

• No citing papers are available for this paper.